We are live on
!
Find out more
PPBT
Purple Biotech
PPBT
PPBT
1 hedge funds and large institutions have $15K invested in Purple Biotech in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
150% more capital invested
Capital invested by funds: $6K → $15K (+$9K)
0% more funds holding
Funds holding: 1 → 1 (0)
Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
UBS Group
Zurich,
Switzerland
| $11K | – | – | – |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
3
Citigroup
New York
| $1K | – | – | – |
|
PPBT Hedge Fund Activity: Q1 2016 in Review
1 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q1 2016, worth a combined $15K — up 150% from $6K a quarter earlier.
Fund positioning in PPBT was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
- 1 institutional investor held Purple Biotech (PPBT) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $15K of Purple Biotech stock for Q1 2016, up 150% quarter-over-quarter.
- 0 funds opened new Purple Biotech positions in Q1 2016 and 0 closed out.
Based on aggregated 13F filings for Q1 2016.